Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
inhaler medication
|
| gptkbp:activeIngredient |
gptkb:mometasone_furoate
gptkb:indacaterol glycopyrronium |
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:European_Union
gptkb:United_Kingdom |
| gptkbp:ATCCode |
R03AK14
|
| gptkbp:containsICS |
gptkb:mometasone_furoate
|
| gptkbp:containsLABA |
gptkb:indacaterol
|
| gptkbp:containsLAMA |
glycopyrronium
|
| gptkbp:drugClass |
combination asthma therapy
|
| gptkbp:form |
dry powder inhaler
|
| https://www.w3.org/2000/01/rdf-schema#label |
Enerzair Breezhaler
|
| gptkbp:indication |
asthma
|
| gptkbp:marketingAuthorizationHolder |
gptkb:Novartis
|
| gptkbp:notRecommendedFor |
relief of acute asthma symptoms
|
| gptkbp:prescriptionStatus |
prescription only
|
| gptkbp:routeOfAdministration |
inhalation
|
| gptkbp:usedFor |
maintenance treatment of asthma
|
| gptkbp:bfsParent |
gptkb:Enerzair
|
| gptkbp:bfsLayer |
6
|